about Synerkine Pharma

Synerkine Pharma is a Dutch biopharmaceutical company developing a novel class of biologics, called Synerkines, which connect different cytokines and enhance their activity through a unique mode of action. By combining the optimal cytokines in one molecule, Synerkine Pharma is establishing a portfolio of Synerkine therapeutics.

Currently our R&D pipeline contains two lead Synerkines. Our first Synerkine, SK-01, connects IL-4 and IL-10 and has the potential to become a disease-modifying therapy for the treatment of chronic pain. The second Synerkine, SK-02, connects IL-13 with IL-4, which has the potential to transform the treatment of Chemotherapy-Induced Peripheral Neuropathy (CIPN).

Synerkine Pharma was founded in 2018 as a spin-off company from the University Medical Center Utrecht.